Skip to content
DataLookout
Menu

NCT03994796

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 55 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Oct 30, 2026
    • Secondary endpoints revised (10)
    • Site details revised at 1 of 435 sites
  2. Notable Eligibility criteria expanded, about 36 words
    • Primary completion date changed from estimate of Oct 2026 to Nov 13, 2025
    • Study description revised
    • Site details revised at 43 of 435 sites
  3. Notable Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: estimated 186 to confirmed 50
    v53
  4. Minor Study sites revised (435)v52
  5. Minor Study sites revised (435)v50
Show 41 earlier versionsHide 41 earlier versions
  1. Minor Study sites revised (435)v48
  2. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Interim analysis
    • Study sites: 437 to 435
    v46
  3. Minor Site details revised at 7 of 437 sitesv45
  4. Minor Study sites revised (437)v44
  5. Notable Primary completion date: Oct 2025 to Oct 2026
    • Start date: Aug 15, 2019 to Oct 17, 2019
    • Study completion date: Jun 2026 to Jun 2028
    • Site details revised at 178 of 437 sites
    v43
  6. Notable Primary completion date: Oct 2024 to Oct 2025
    • Study sites: 426 to 437
    • Study completion date: Jun 2025 to Jun 2026
    v42
  7. Minor Study sites revised (426)v41
  8. Minor Study sites revised (426)v40
  9. Minor Study sites: 424 to 426v39
  10. Minor Study sites revised (424)v38
  11. Minor Study sites: 417 to 424v37
  12. Minor Study sites: 416 to 417v36
  13. Minor Study sites: 405 to 416v35
  14. Notable Eligibility criteria expanded, about 433 wordsv34 Show 4 more changesShow less
    • Enrollment target: 150 to 186
    • Interventions: Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug) to Abemaciclib (Drug), Adagrasib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug)
    • Study description expanded, about 63 words
    • Study arms: 3 to 4
  15. Minor Study sites: 387 to 405v33
  16. Minor Study sites: 386 to 387v32
  17. Minor Site details revised at 5 of 386 sitesv31
  18. Minor Site details revised at 18 of 386 sitesv30
  19. Minor Study sites: 380 to 386v29
  20. Minor Site details revised at 50 of 380 sitesv28
  21. Minor Site details revised at 17 of 380 sitesv27
  22. Minor Study sites: 379 to 380v26
  23. Minor Site details revised at 189 of 379 sitesv25
  24. Minor Site details revised at 14 of 379 sitesv24
  25. Minor Study sites: 369 to 379v23
  26. Minor Study sites: 365 to 369v22
  27. Notable Primary completion date: Jul 2021 to Oct 2024v21
  28. Minor Study sites: 355 to 365
    • Interventions: Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor GDC-0084 (Drug) to Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug)
    v20
  29. Minor Study sites: 354 to 355v19
  30. Minor Study sites: 351 to 354v18
  31. Minor Study sites: 349 to 351v17
  32. Minor Study sites: 347 to 349v16
  33. Minor Study sites: 348 to 347v15
  34. Minor Study sites: 342 to 348v13
  35. Minor Study sites: 330 to 342v12
  36. Minor Study sites: 309 to 330v11
  37. Minor Study sites: 306 to 309v10
  38. Minor Study sites: 304 to 306v9
  39. Minor Study sites: 297 to 304v8
  40. Minor Study sites: 283 to 297v7
  41. Minor Study sites: 254 to 283v6
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate in the Brain
Timeframe: Up to 5 years

Secondary (10)

Systemic Response for Extracranial Disease
Clinical Benefit Rate for Central Nervous System (CNS)
Clinical Benefit Rate for Extracranial Disease
Duration of Response for Brain Metastases
Duration of Response for Extracranial Disease
Show 5 moreShow less
Progression-free Survival (PFS) - Intracranial
Progression-free Survival (PFS) - Extracranial
Site of First Progression
Overall Survival
Incidence of Adverse Events

Arms and interventions

Arm I (CDK gene mutation)Experimental

Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Arm II (PI3K gene mutation)Experimental

Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Arm III (NTRK/ROS1 gene mutation)Experimental

Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Arm IV (KRAS G12C mutation)Experimental

Patients receive adagrasib (MRTX849) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drugs: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib

Sites

435 sites in 1 country